Efficacy of Tranexamic Acid on Blood Loss During Rhinoplasty

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111219008458N2

Enrollment

Registered

2021-04-13

Start date

2021-05-22

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinoplasty.

Interventions

Intervention 1: Intervention group: Patients receiving Tranexamic Acid (Tranexip, Caspian Tamin Pharmaceutical) 10mg/kg IV right before surgery, and after induction of anesthesia. Intervention 2: Cont

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Without any systemic disease ASA I category

Exclusion criteria

Exclusion criteria: Drug abuser or addict Renal or Liver failure Hemostatic disorders History of convulsion Hypersensitivity to Tranexamic Acid Pregnancy

Design outcomes

Primary

Measure	Time frame
Amount of bleeding. Timepoint: Before intervention, Immediately after intervntion. Method of measurement: Hemoglobin concentration and blood volume in suction.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHesam Panahi

Shahre-kord University of Medical Sciences

hesam_panahi_87@yahoo.com+98 38 3333 1471

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 21, 2026